Elsevier

Dermatologic Clinics

Volume 32, Issue 4, October 2014, Pages 467-476
Dermatologic Clinics

Impact of Hyperhidrosis on Quality of Life and its Assessment

https://doi.org/10.1016/j.det.2014.06.004Get rights and content

Section snippets

Key points

  • Primary focal hyperhidrosis severely affects many aspects of daily life including emotional well-being, interpersonal relationships, leisure activities, personal hygiene, work and productivity, and self-esteem.

  • For evaluation of its impact on patients, disease-specific questionnaires, such as the Hyperhidrosis Disease Severity Scale, the Clinical Protocol for Quality of Life, and the comprehensive Hyperhidrosis Impact Questionnaire, have been developed.

  • Limitations of hyperhidrosis as a

Hyperhidrosis Disease Severity Scale

The Hyperhidrosis Disease Severity Scale (HDSS) is a single-item question allowing 4 gradations of the tolerability of sweating and its interference with daily activities (Table 1). This simple, validated diagnostic tool offers a quick way to estimate the impairment of QoL caused by sweating. A score of 3 or 4 indicates severe hyperhidrosis, a score of 2 moderate hyperhidrosis, and a score of 1 absence of hyperhidrosis.

The HDSS was introduced in 2004 to determine the prevalence of hyperhidrosis

Dermatology Life Quality Index

The Dermatology Life Quality Index (DLQI) developed by Finlay and Khan66 in 1994 is the most frequently used instrument to measure the effects of dermatologic diseases on QoL. The simple, validated questionnaire consists of 10 items covering 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Each item has 4 gradations (3, very much; 2, a lot; 1, a little; 0, not at all/not relevant). Total scores range from 0 to 30, with higher

Short Form Health Survey (36 Item and 12 Item)

The 36-item Short Form Health Survey (SF-36) and an abbreviated variant of it, the 12-item Short Form Health Survey (SF-12), are valid and reliable patient-reported tools widely used for evaluation of the health-related QoL of an individual.77 The SF-36 consists of multiple-choice questions on 8 health domains (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health). Answers are

Assessment of special impairments

Anxiety, depression, and social phobia profiles were repeatedly assessed in patients with hyperhidrosis.31, 49, 76, 84, 87 Weber and colleagues76 applied the State-Trait Anxiety Inventory G Form X2 (STAI), the Social Phobia Scale (SPS), the Symptom Checklist 90R (SCL-90-R) of Derogatis, and the Hospital Anxiety and Depression Scale (HADS-D) to 70 patients with different types of PFH. Only the mean value for SPS was slightly greater than the normal range, but values of all instruments

Summary

Hyperhidrosis in general, and PFH in particular as the most important entity within its scope, are common conditions that are often detrimental to patients’ social, psychological, professional, and physical well-being. Beyond objective measurement of increased sweat production and demarcation of affected sites and areas, the real impact of the disease can only be recognized by assessment of the reduction in QoL. Significant progress in treatment of PFH has been achieved by the introduction of

First page preview

First page preview
Click to open first page preview

References (89)

  • N. Wolosker et al.

    Quality of life before surgery is a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis

    J Vasc Surg

    (2010)
  • N. Wolosker et al.

    Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy

    J Vasc Surg

    (2012)
  • V. Ambrogi et al.

    Bilateral thoracoscopic T2 to T3 sympathectomy versus botulinum injection in palmar hyperhidrosis

    Ann Thorac Surg

    (2009)
  • N. Wolosker et al.

    The use of oxybutynin for treating axillary hyperhidrosis

    Ann Vasc Surg

    (2011)
  • N. Wolosker et al.

    A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis

    J Vasc Surg

    (2012)
  • N. Wolosker et al.

    Effectiveness of oxybutynin for treatment of hyperhidrosis in overweight and obese patients

    Rev Assoc Med Bras

    (2013)
  • J. Loscertales et al.

    Thoracoscopic sympathectomy for palmar hyperhidrosis. Immediate results and postoperative quality of life

    Arch Bronconeumol

    (2004)
  • R. Ramos et al.

    [Primary hyperhidrosis and anxiety: a prospective preoperative survey of 158 patients]

    Arch Bronconeumol

    (2005)
  • T.M. Boley et al.

    The effect of thoracoscopic sympathectomy on quality of life and symptom management of hyperhidrosis

    J Am Coll Surg

    (2007)
  • A. Campanati et al.

    Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study

    Clin Ther

    (2003)
  • F.G. Bechara et al.

    Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage

    J Am Acad Dermatol

    (2007)
  • M.M. Chren et al.

    Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness

    J Invest Dermatol

    (1996)
  • O. Young et al.

    Evaluation of the impact of transthoracic endoscopic sympathectomy on patients with palmar hyperhydrosis

    Eur J Vasc Endovasc Surg

    (2003)
  • K. Kumagai et al.

    Health-related quality of life after thoracoscopic sympathectomy for palmar hyperhidrosis

    Ann Thorac Surg

    (2005)
  • J. Schmidt et al.

    Endoscopic thoracic sympathectomy for severe hyperhidrosis: impact of restrictive denervation on compensatory sweating

    Ann Thorac Surg

    (2006)
  • R. Adar et al.

    Palmar hyperhidrosis and its surgical treatment: a report of 100 cases

    Ann Surg

    (1977)
  • P. Mindus

    Livskvalitet och hyperhidros

    Läkartidningen

    (1980)
  • H. Hamm et al.

    Primary focal hyperhidrosis: disease characteristics and functional impairment

    Dermatology

    (2006)
  • N. Solish et al.

    Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life

    Dermatol Surg

    (2005)
  • A. Campanati et al.

    Treatment of focal idiopathic hyperhidrosis with botulinum toxin type A: clinical predictive factors of relapse-free survival

    J Eur Acad Dermatol Venereol

    (2011)
  • C. Müller et al.

    Efficacy and safety of methantheline bromide (Vagantin(®)) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial

    J Eur Acad Dermatol Venereol

    (2013)
  • N. Solish et al.

    A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee

    Dermatol Surg

    (2007)
  • W.O. Kim et al.

    Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk

    Dermatol Surg

    (2009)
  • W.O. Kim et al.

    Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients

    Acta Derm Venereol

    (2010)
  • K.F. Kwong et al.

    Stratified analysis of clinical outcomes in thoracoscopic sympathicotomy for hyperhidrosis

    Ann Thorac Surg

    (2008)
  • M. Amir et al.

    Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results

    Isr J Psychiatry Relat Sci

    (2000)
  • J.R. De Campos et al.

    Quality of life, before and after thoracic sympathectomy: report on 378 operated patients

    Ann Thorac Surg

    (2003)
  • N. Wolosker et al.

    Is sympathectomy at T4 level better than at T3 level for treating palmar hyperhidrosis?

    J Laparoendosc Adv Surg Tech A

    (2008)
  • A. Ishy et al.

    Objective evaluation of patients with palmar hyperhidrosis submitted to two levels of sympathectomy: T3 and T4

    Interact Cardiovasc Thorac Surg

    (2011)
  • S. Neves et al.

    Long-term comparison of video-assisted thoracic sympathectomy and clinical observation for the treatment of palmar hyperhidrosis in children younger than 14

    Pediatr Dermatol

    (2012)
  • P. Loureiro Mde et al.

    Endoscopic lumbar sympathectomy for women: effect on compensatory sweat

    Clinics (Sao Paulo)

    (2008)
  • F.G. Wang et al.

    Comparison of compensatory sweating and quality of life following thoracic sympathetic block for palmar hyperhidrosis: electrocautery hook versus titanium clip

    Chin Med J (Engl)

    (2011)
  • H.H. Lee et al.

    Efficacy of glycopyrrolate in primary hyperhidrosis patients

    Korean J Pain

    (2012)
  • P. Panhofer et al.

    Long-term outcomes after endothoracic sympathetic block at the T4 ganglion for upper limb hyperhidrosis

    Br J Surg

    (2013)
  • Cited by (0)

    Disclosure Statement: The author has been investigator in clinical trials sponsored by Allergan Co, United Kingdom, and Ipsen Pharma GmbH, Germany. He has received grants from Allergan Co for hyperhidrosis research and has been a consultant for Pharm-Allergan GmbH, Germany. He has received speaker’s honoraria from Allergan and from the International Hyperhidrosis Society.

    View full text